Form 8-K - Current report:
SEC Accession No. 0001753926-25-000035
Filing Date
2025-01-06
Accepted
2025-01-06 17:25:32
Documents
14
Period of Report
2024-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K g084643_8k.htm   iXBRL 8-K 46947
2 EXHIBIT 10.1 g084643_ex10-1.htm EX-10.1 53789
  Complete submission text file 0001753926-25-000035.txt   287294

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lipo-20241231.xsd EX-101.SCH 3012
4 XBRL LABEL FILE lipo-20241231_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE lipo-20241231_pre.xml EX-101.PRE 22357
16 EXTRACTED XBRL INSTANCE DOCUMENT g084643_8k_htm.xml XML 3849
Mailing Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208
Business Address 400 N LEXINGTON ST STE LL103 PITTSBURGH PA 15208 412-901-0315
LIPELLA PHARMACEUTICALS INC. (Filer) CIK: 0001347242 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41575 | Film No.: 25512430
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)